4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-21-012661
Chief Business Officer sold 15,000 shares at an average $35.49 ($532,352)
- Chief Business Officer acquired 15,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Beaurang Pierre · Chief Business Officer
Table I: Non-derivative
8 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-02-18 | Exercise or conversion : show line 1 in the form | +9,107 | $0.84 | $7,650 | 9,107 | D |
| 2021-02-18 | Exercise or conversion : show line 2 in the form | +3,797 | $7.26 | $27,566 | 12,904 | D |
| 2021-02-18 | Exercise or conversion : show line 3 in the form | +2,096 | $9.57 | $20,059 | 15,000 | D |
| 2021-02-18 | Sale : show line 4 in the form | −2,647 | $34.19 | $90,496 | 12,353 | D |
| 2021-02-18 | Sale : show line 5 in the form | −4,553 | $35.02 | $159,454 | 7,800 | D |
| 2021-02-18 | Sale : show line 6 in the form | −6,400 | $35.99 | $230,328 | 1,400 | D |
| 2021-02-18 | Sale : show line 7 in the form | −1,000 | $36.92 | $36,924 | 400 | D |
| 2021-02-18 | Sale : show line 8 in the form | −400 | $37.88 | $15,150 | 0 | D |
| Open-market sales · 15,000 sh · avg $35.49 · $532,352 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2021-02-18 | Exercise or conversion : show line 9 in the form Employee Stock Option (right to buy) | −9,107 | $0.84 | 2026-01-27 | 9,107 | 14,226 | D |
| 2021-02-18 | Exercise or conversion : show line 10 in the form Employee Stock Option (right to buy) | −3,797 | $7.26 | 2030-02-26 | 3,797 | 72,869 | D |
| 2021-02-18 | Exercise or conversion : show line 11 in the form Employee Stock Option (right to buy) | −2,096 | $9.57 | 2030-06-27 | 2,096 | 14,678 | D |
Loading xslF345X03/doc4.xml…